ARLINGTON, Va.--(BUSINESS WIRE)--Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announces that it has established agreements with Centocor Research & Development, Inc., for the preclinical evaluation of certain therapeutic agents in Centocor’s clinical development pipeline. As part of the agreements, Centocor will utilize Champions Biotechnology’s Biomerk Tumorgrafts™ to evaluate promising antibodies.
